The Most Common Infections and Their Treatments in Oncology Patients at Uppsala University Hospital Year 2020-2022 - a Retrospective Registry Study Background: There are two types of infections of interest to this study, these are healthcareassociated infections and community-acquired infections. It is common for oncology patients to suffer from various difficult-to-treat infections caused by bacteria, viruses, and fungi. Death due to infections is the second most common cause in oncology patients. Antibiotics are a drug class of the type of antibacterial drugs that are widely used today. Aim: The purpose of this study is to describe the frequency of an antibiotic use with a focus on the substance selection and indications as well as the resistance patterns in oncology patients at Akademiska hospital between the years 2020 and 2022. Methods: The study was designed as a descriptive registry study, where different data sources were used as a method. Methods used to analyze the data were quantitative methods, providing a quantifiable answer to the sub-questions using numbers and structured data. Results: The study indicated that the most common infections in oncology patients during these years were other community-acquired infection, urinary tract infection without fever, other skin/soft tissue/skeletal infections, and pneumonia. The most common treatment differed depending on which database the information was taken from. According to the first database, the most common preparations were Piperacillin/Tazobactam, Ciprofloxacin and Pivmecillinam. According to the other database, the most common preparations were Sulfamethoxazole/Trimethoprim, Ciprofloxacin and Piperacillin/Tazobactam. Of oncology patients treated with cancer drugs, 53% needed antibiotic treatment in hospital and 93% either administered in hospital or prescribed at home. Conclusions: Many oncology patients suffer from infections that require treatment. This entails a high risk of antibiotic resistance. More study is needed for this patient group to optimize treatment and reduce relapse.
| Identifer | oai:union.ndltd.org:UPSALLA1/oai:DiVA.org:uu-506856 |
| Date | January 2023 |
| Creators | Al-Nuaimi, Ateka |
| Publisher | Uppsala universitet, Institutionen för farmaci |
| Source Sets | DiVA Archive at Upsalla University |
| Language | Swedish |
| Detected Language | English |
| Type | Student thesis, info:eu-repo/semantics/bachelorThesis, text |
| Format | application/pdf |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0028 seconds